165 related articles for article (PubMed ID: 37712677)
21. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.
Moon I; LoPiccolo J; Baca SC; Sholl LM; Kehl KL; Hassett MJ; Liu D; Schrag D; Gusev A
Nat Med; 2023 Aug; 29(8):2057-2067. PubMed ID: 37550415
[TBL] [Abstract][Full Text] [Related]
22. [Molecular diagnostic methods designed for clinical approach to cancer of unknown origin].
Fujita Y; Nishio K
Gan To Kagaku Ryoho; 2009 Jun; 36(6):923-6. PubMed ID: 19542713
[TBL] [Abstract][Full Text] [Related]
23. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
24. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
25. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
26. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
27. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
Staub E; Buhr HJ; Gröne J
Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
[TBL] [Abstract][Full Text] [Related]
28. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.
Pentheroudakis G; Pavlidis N; Fountzilas G; Krikelis D; Goussia A; Stoyianni A; Sanden M; St Cyr B; Yerushalmi N; Benjamin H; Meiri E; Chajut A; Rosenwald S; Aharonov R; Spector Y
Mol Cancer; 2013 Jun; 12():57. PubMed ID: 23758919
[TBL] [Abstract][Full Text] [Related]
29. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
30. Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.
Kim KW; Krajewski KM; Jagannathan JP; Nishino M; Shinagare AB; Hornick JL; Ramaiya NH
AJR Am J Roentgenol; 2013 Mar; 200(3):484-92. PubMed ID: 23436835
[TBL] [Abstract][Full Text] [Related]
31. Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists.
Karapetis CS; Guccione L; Tattersall MH; Gooden H; Vajdic CM; Lambert S; Robotin M; Mileshkin L; Schofield P
Intern Med J; 2017 Apr; 47(4):408-414. PubMed ID: 28101916
[TBL] [Abstract][Full Text] [Related]
32. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.
Nguyen L; Van Hoeck A; Cuppen E
Nat Commun; 2022 Jul; 13(1):4013. PubMed ID: 35817764
[TBL] [Abstract][Full Text] [Related]
33. An integrated tool for determining the primary origin site of metastatic tumours.
Santos MTD; Souza BF; Cárcano FM; Vidal RO; Scapulatempo-Neto C; Viana CR; Carvalho AL
J Clin Pathol; 2018 Jul; 71(7):584-593. PubMed ID: 29248889
[TBL] [Abstract][Full Text] [Related]
34. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.
Monzon FA; Koen TJ
Arch Pathol Lab Med; 2010 Feb; 134(2):216-24. PubMed ID: 20121609
[TBL] [Abstract][Full Text] [Related]
36. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
37. Cancers of unknown primary origin: current perspectives and future therapeutic strategies.
Stella GM; Senetta R; Cassenti A; Ronco M; Cassoni P
J Transl Med; 2012 Jan; 10():12. PubMed ID: 22272606
[TBL] [Abstract][Full Text] [Related]
38. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Profiling of CUP.
Cancer Discov; 2016 Nov; 6(11):1203. PubMed ID: 27658716
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
Kodaira M; Yonemori K; Shimoi T; Yoshida A; Yoshida M; Kitano A; Shimomura A; Yunokawa M; Shimizu C; Takiguchi Y; Fujiwara Y; Tamura K
BMC Cancer; 2018 Feb; 18(1):176. PubMed ID: 29433539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
